A new study from Stanford researchers reveals a non-invasive urine test that can accurately detect residual bladder cancer ...

A refined liquid biopsy that accounts for age-related background mutations has enabled clinicians to identify patients with ...

Groundbreaking study published in The Journal of Molecular Diagnostics paves the way for noninvasive screening tools that improve patient comfort and outcomes Bladder cancer remains a major clinical ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

“This early clinical data validates a core premise: the physics of cancer can reveal what molecular tests routinely miss,” said Jean Pham, Founder & CEO of Cellens. “Our goal is to shift the standard ...

RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC. Induction ipilimumab plus nivolumab followed by consolidating chemoradiotherapy as bladder-sparing ...

A groundbreaking noninvasive urine test is transforming how doctors predict bladder cancer treatment outcomes. This ...

Bladder cancer does not always announce itself with dramatic pain or a sudden health crisis. In many people, the earliest bladder cancer symptoms look ordinary, brief, or easy to dismiss. A little ...

Indiana University cancer specialists just helped put Indianapolis on the global oncology map, serving as authors and ...